$VIVS News
Last published 1d ago
- 1d agoVIVSVivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual MeetingGlobeNewswireCompany to feature two scientific poster presentations highlighting that its multiparametric approach delivers superior predictive power for both its DILI risk stratification and gastrointestinal toxicity profiling using its proprietary NAMkind™ Liver and Intestine platforms
- 1w agoVIVSVivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human TestGlobeNewswireSAN DIEGO and HYDERABAD, India, Nov. 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) ("VivoSim" or "Company"), a provider of AI-enabled New Approach Methodologies (NAMs) for preclinical
- 3w agoVIVSVivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker ProfilingGlobeNewswireSAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for
- 1mo agoVIVSVivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing MethodsGlobeNewswireSAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for
- 1mo agoVIVSVivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCsGlobeNewswireSAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) ("VivoSim" or the "Company") unveils new clinical benchmark data at the 58th Congress of the European Societies of
- 2mo agoVIVSVivoSim Labs to Add Rat Liver Model to NAMkind PlatformGlobeNewswireSAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for
- 3mo agoVIVSVivoSim Provides Financial and Listing Compliance UpdateGlobeNewswireSAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for
- 3mo agoVIVSVivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing ServicesGlobeNewswireSAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today
- 3mo agoVIVSVivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional InvestorGlobeNewswireSAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for
- 3mo agoNTHIERNAVIVSLLYThree Biotechs Deliver Catalysts to WatchGlobeNewswireDENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ:NTHI), Ernexa Therapeutics (NASDAQ:ERNA), and VivoSim Labs (NASDAQ:VIVS) highlight three distinct
- 3mo agoVIVSVivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027GlobeNewswireSAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for
- 4mo agoVIVSVivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology MeetingGlobeNewswireSAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today
- 6mo agoVIVSVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingGlobeNewswireSAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the
- 7mo agoVIVSVivoSim Announces Pricing of up to a $4 Million Public OfferingGlobeNewswireSAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS), (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the
- 7mo agoVIVSVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsGlobeNewswireSAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced at
- 8mo agoVIVSVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesGlobeNewswireSAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the
- 9mo agoVIVSVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoGlobeNewswireSAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it
- 9mo agoVIVSVivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaGlobeNewswireSAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced
- 10mo agoVIVSVivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific OfficerGlobeNewswireSAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and
- 1y agoVIVSVivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerGlobeNewswireSAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and
- 1y agoVIVSVivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week ConferenceGlobeNewswireSAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim") announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue
- 1y agoVIVSVivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week ConferenceGlobeNewswireSAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company") announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial
- 1y agoONVOVIVSVivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ MarketGlobeNewswireSAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will